Even when breakthrough medicines are ready, it often takes over a year for them to reach patients. This delay is primarily caused by scattered data, outdated tools, and manual workflows that slow down everything from pricing documents to reimbursement strategies. Munich-based platform Cellbyte provides pharmaceutical teams with a single AI-driven system that centralises all information.
Today, Cellbyte announced it has secured $2.75 million in seed funding to address one of the pharmaceutical industry’s biggest bottlenecks: the lengthy wait between regulatory approval and a drug’s commercial launch. The funding round was led by Frontline Ventures and included participation from Y Combinator, Pace Ventures, Saras Capital, and Springboard Health Angels.
“The success of a drug’s entire lifecycle is decided in its launch sequence. The traction Cellbyte has secured with some of the world’s biggest pharmaceutical companies since its launch shows the industry is ready to rethink drug launch workflows and adopt faster, higher quality and cost-effective processes,” said Felix Steinbrenner, Co-CEO and Co-Founder at Cellbyte.
Helping pharmaceutical companies accelerate drug launches
Founded in 2024 by Daniel Moreira, Felix Steinbrenner, and Samuel Moreira, Cellbyte combines hands-on pharmaceutical expertise with advanced AI engineering. Its platform streamlines the pricing, market access, and regulatory workflows involved in drug launches by automating data extraction and insight generation.
Unlike Exscientia, CytoReason, or Confity, Cellbyte’s system offers teams a deeper, continuously updated view of the market. It integrates data from clinical, pricing, regulatory, and Health Technology Assessment (HTA) sources, allowing users to analyse millions of data points in real time through natural language queries.
The platform also offers instant translations, helping overcome international language barriers in pharmaceutical research.
Cellbyte has already secured contracts with major pharmaceutical brands such as Bayer and continues to expand its customer base. Moreira added that Pricing and Market Access remain stubbornly slow despite major advances in other areas of drug development. “Now, generative AI is changing that, and we’re proud to be driving this shift.”
What’s next?
Looking ahead, the new funding will enable Cellbyte to triple its headcount, expand its engineering capabilities, and meet growing demand across Europe and the U.S. The company’s long-term vision is to become the operating system for commercial pharmaceutical teams worldwide.
